Peptides
Evidence: Emerging (strong preclinical)
MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.
Standard: Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
Loading: Research indicates 10 mg daily for the first 1-2 weeks.
Maintenance: Research indicates 5 mg three times weekly.
Administration: subcutaneous
Timing: Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
Duration: 8-16 week cycles.
MOTS-c is one of the most exciting mitochondrial-derived peptides, functioning as a genuine exercise mimetic. It was discovered by Dr. Changhan Lee at USC. The 11.9-fold increase in skeletal muscle MOTS-c after exercise suggests it is a key mediator of exercise benefits. MOTS-c levels decline with age, correlating with metabolic decline. The 5-Amino-1MQ + MOTS-c fat loss stack combines NNMT inhibition with AMPK activation for comprehensive metabolic optimization. MOTS-c also shows anti-aging and insulin-sensitizing properties beyond fat loss.
Research-grade supplier. Compounding pharmacy availability increasing. Store at -20C lyophilized.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →